Adrienne G. Waks

2 months ago | acsjournals.onlinelibrary.wiley.com | Adrienne G. Waks |Paolo Tarantino |Emily Chen |Rachel A. Freedman

INTRODUCTION Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 15%–20% of invasive breast cancers and is an unfavorable prognostic factor.1 The administration of HER2-directed therapy has transformed outcomes for patients who have HER2-positive breast cancer.

Aug 23, 2024 | onclive.com | Adrienne G. Waks

CommentaryVideoAugust 23, 2024Author(s):Fact checked by:Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease. Adrienne G.

Aug 21, 2024 | targetedonc.com | Adrienne G. Waks

The DAPHNe trial (NCT03716180) investigated the prevalence and dynamics of circulating tumor DNA (ctDNA) in patients with early-stage HER2-positive breast cancer undergoing neoadjuvant therapy. In the study, 92% of patients had detectable ctDNA at baseline, suggesting widespread minimal residual disease (MRD). Neoadjuvant therapy, primarily consisting of trastuzumab (Herceptin) and pertuzumab (Perjeta) was highly effective in clearing ctDNA, regardless of the initial tumor stage.

Aug 13, 2024 | onclive.com | Adrienne G. Waks

CommentaryVideoAugust 13, 2024Author(s):Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer. Adrienne G.

Jul 17, 2024 | onclive.com | Adrienne G. Waks

Author(s):Adrienne G. Waks, MD, discusses implications of the potential use of first-line T-DXd in HER2-positive breast cancer. Adrienne G. Waks, MD, physician, associate director of Clinical Research, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses key questions and potential implications for replacing the prior first-line standard of care (SOC) with fam-trastuzumab-deruxtecan-nxki (T-DXd) in HER2-positive breast cancer.